pgc-1 & muscle mitochondrial dysfunction in diabetes: aims 1-4

Conditions: Type2 Diabetes; Obesity

Summary: we are trying to understand how insulin (a type of hormone in the body that regulates how the body regulates how one metabolizes protein and carbohydrates) and exercise alter proteins involved in energy production and metabolism in skeletal muscle.

(aims 1-3) we are trying to understand how insulin (a type of hormone in the body that regulates how the body regulates how one metabolizes protein and carbohydrates) and exercise alter proteins involved in energy production and metabolism in skeletal muscle. by studying this, they hope to better understand the causes of insulin resistance and type 2 diabetes insulin is a hormone that is produced normally in the body and causes blood sugar to return to normal after eating. insulin resistance is a state when the body is not using insulin correctly, and more insulin is needed to keep blood sugar concentrations normal. insulin resistance can lead to type 2 diabetes. type 2 diabetes is a disease in which blood sugar levels are too high. our studies may help to find out why some people develop type 2 diabetes and how exercise may prevent this disease. (aim 4) we are asking patients from aims 1-3 to take part in this research study because they have high triglycerides that could be treated anyway with fibrates, and they do not have diabetes. triglycerides and cholesterol are the two main kinds of fat that are in blood. people who have high triglycerides have some health risks and are sometimes treated with drugs called "fibrates". this drug turns on a protein in ones body that controls the activity of some of the genes that make it easier for their liver to get rid of triglycerides. we think that maybe this same gene, in ones muscle, can lower the ability of genes in ones muscle to respond beneficially to exercise, but we don't know if this is true.

Eligibility criteria:
aims 1-3. 1. age 30-59 2. bmi: lean, bmi less than or equal to 25; obese, bmi between 30- 50; type 2 diabetic, bmi between 30- 50. 3. subjects must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent. 4. subjects may be of either sex with age as described in each protocol. female subjects must be non-lactating and will be eligible only if they have a negative pregnancy test throughout the study period. 5. subjects must range in age as described in each specific protocol. 6. subjects must have the following laboratory values: 1. hematocrit ≥ 35 vol% 2. serum creatinine ≤ 1.6 mg/dl 3. ast (sgot) \< 2 times upper limit of normal 4. alt (sgpt) \< 2 times upper limit of normal 5. alkaline phosphatase \< 2 times upper limit of normal 6. triglycerides \< 150 mg/dl for nondiabetics (except for aim 4). 7. triglycerides \<300 for diabetics (except for aim 4) 8. inr ≤ 1.3 aim 4 1. age 30-59 2. bmi: lean, bmi less than or equal to 25; obese, bmi between 30- 50. 3. patients may have normal or impaired glucose tolerance. 4. subjects must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent. 5. subjects may be of either sex with age as described in each protocol. female subjects must be non-lactating and will be eligible only if they have a negative pregnancy test throughout the study period. 6. subjects must have the following laboratory values: 1. hematocrit ≥ 35 vol% 2. serum creatinine ≤ 1.6 mg/dl 3. ast (sgot) \< 2 times upper limit of normal 4. alt (sgpt) \< 2 times upper limit of normal 5. alkaline phosphatase \< 2 times upper limit of normal 6. triglycerides \> 300 mg/dl for nondiabetics, \> 250 mg/dl for impaired glucose tolerance. 7. inr ≤ 1.3 7. patients must be prescribed gemfibrozil from their doctor exclusion criteria: * 1. subjects must not be receiving any of the following medications: thiazide or furosemide diuretics, beta-blockers, or other chronic medications with known adverse effects on glucose tolerance levels unless the patient has been on a stable dose of such agents for the past three months before entry into the study. subjects may be taking a stable dose of estrogens or other hormonal replacement therapy, if the subject has been on these agents for the prior three months. subjects taking systemic glucocorticoids are excluded. patients with type 2 diabetes will be excluded if they are taking thiazolidinediones, but may be taking sulfonylureas or other medications known to work through effects on insulin sectretion. 2. subjects receiving gemfibrozil must not also be receiving a statin. 3. subjects with a history of clinically significant heart disease (new york heart classification greater than grade ii; more than non-specific st-t wave changes on the ekg), peripheral vascular disease (history of claudication), or pulmonary disease (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation) will not be studied. 4. recent systemic or pulmonary embolus, untreated high-risk proliferative retinopathy, recent retinal hemorrhage, uncontrolled hypertension, systolic bp\>180, diastolic bp\>105, autonomic neuropathy, resting heart rate \>100, electrolyte abnormalities.